Abera Bioscience AB
The answer first
Does Abera Bioscience beat the market?
Yes, Abera Bioscience has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 35% of Nordic stocks
- Quality66
- Value2
- Trend65
No. 92 of 195 in healthcare
Max for seven days
Follow Abera Bioscience with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 20 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Abera Bioscience
Your first answer is free, no account needed.
Do you own Abera Bioscience, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Abera Bioscience and a few more. Free, no card.
Super Stock+45.3%In short
- Abera Bioscience has risen 23.4% over the past year, including dividends.
- Overall, Abera Bioscience ranks better than 35% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 86.6%. The price is 75.7% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 35% of Nordic stocks.
No. 92 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 96 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity–
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−117.1%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 185 of 197 in healthcareTypical in healthcare: 19Typical in the Nordics: 50
- P/BPrice divided by equity7.9
- P/SPrice divided by sales–
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Medium The share price has moved about like most stocks over the last year.
No. 57 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−11.0%
- 6 months+6.4%
- 9 months+14.6%
- 12 months+23.4%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Abera Bioscience
Abera Bioscience AB is a company in healthcare, listed on Nasdaq Stockholm. By market value, Abera Bioscience is number 76 of 137 companies in healthcare on Nasdaq Stockholm. Abera Bioscience has not paid a dividend in the past twelve months. Of the three measures in the ranking, Abera Bioscience is strongest on quality, better than 66% of Nordic stocks. The share trades in SEK. It has around 5 employees.
Abera Bioscience AB (publ), a platform and vaccine development company, develops vaccines based on its proprietary and patented platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine. The company also develops projects in Flu, Diarrhea Chlamydia, ETEC, Covid-19, and Tuberculosis. The company was incorporated in 2012 and is headquartered in Uppsala, Sweden.


See the full analysis of Abera Bioscience.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card